Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this study is to determine the amount of ABT-614 in the cerebral spinal fluid and blood after administration of a single dose and after administration of daily doses for 14 days in healthy volunteers.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Single Dose (Part 1) | Experimental |
| |
| Multiple Dose (Part 2) | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ABT-614 | Drug | Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Safety and Tolerability Assessments (e.g., clinical laboratory tests, vital signs, adverse event assessment, physical examination) | One day before dosing through day of last dose and up to 72 hrs post-single dose or up to 14 days post-multiple doses | |
| ABT-614 levels in cerebral spinal fluid | 0-24 hrs after single dose or 0-24 hrs after last dose of mulitple-dosing regimen | |
| ABT-614 levels in blood (plasma) | 0-24 hrs after single dose or 0-24 hrs after last dose of mulitple-dosing regimen |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Site Reference ID/Investigator# 22445 | San Antonio | Texas | 78217 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided